Your browser doesn't support javascript.
loading
Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis.
Peloquin, Charles A; Phillips, Patrick P J; Mitnick, Carole D; Eisenach, Kathleen; Patientia, Ramonde F; Lecca, Leonid; Gotuzzo, Eduardo; Gandhi, Neel R; Butler, Donna; Diacon, Andreas H; Martel, Bruno; Santillan, Juan; Hunt, Kathleen Robergeau; Vargas, Dante; von Groote-Bidlingmaier, Florian; Seas, Carlos; Dianis, Nancy; Moreno-Martinez, Antonio; Kaur, Pawandeep; Horsburgh, C Robert.
Afiliação
  • Peloquin CA; Infectious Disease Pharmacokinetics Lab, University of Florida, Gainesville Florida, USA peloquin@cop.ufl.edu.
  • Phillips PPJ; Division of Pulmonary and Critical Care Medicine, University of California San Francisco, San Francisco, California, USA.
  • Mitnick CD; MRC Clinical Trials Unit at UCL, London, United Kingdom.
  • Eisenach K; Department of Global Health & Social Medicine, Harvard Medical School, Boston, Massachusetts, USA.
  • Patientia RF; University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
  • Lecca L; Stellenbosch University and Task Applied Science, Cape Town, South Africa.
  • Gotuzzo E; Socios en Salud Sucursal Peru, Lima, Peru.
  • Gandhi NR; Universidad Peruana Cayetano Heredia, Lima, Peru.
  • Butler D; Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.
  • Diacon AH; Department of Medicine (Infectious Diseases), Emory School of Medicine, Emory University, Atlanta, Georgia, USA.
  • Martel B; Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.
  • Santillan J; Westat, Bethesda, Maryland, USA.
  • Hunt KR; Stellenbosch University and Task Applied Science, Cape Town, South Africa.
  • Vargas D; Socios en Salud Sucursal Peru, Lima, Peru.
  • von Groote-Bidlingmaier F; Universidad Peruana Cayetano Heredia, Lima, Peru.
  • Seas C; Westat, Bethesda, Maryland, USA.
  • Dianis N; Socios en Salud Sucursal Peru, Lima, Peru.
  • Moreno-Martinez A; Stellenbosch University and Task Applied Science, Cape Town, South Africa.
  • Kaur P; Universidad Peruana Cayetano Heredia, Lima, Peru.
  • Horsburgh CR; Westat, Bethesda, Maryland, USA.
Antimicrob Agents Chemother ; 62(10)2018 10.
Article em En | MEDLINE | ID: mdl-30012767
Patients with multidrug-resistant tuberculosis in Peru and South Africa were randomized to a weight-banded nominal dose of 11, 14, 17, or 20 mg/kg/day levofloxacin (minimum, 750 mg) in combination with other second-line agents. A total of 101 patients were included in noncompartmental pharmacokinetic analyses. Respective median areas under the concentration-time curve from 0 to 24 h (AUC0-24) were 109.49, 97.86, 145.33, and 207.04 µg · h/ml. Median maximum plasma concentration (Cmax) were 11.90, 12.02, 14.86, and 19.17 µg/ml, respectively. Higher levofloxacin doses, up to 1,500 mg daily, resulted in higher exposures. (This study has been registered at ClinicalTrials.gov under identifier NCT01918397.).
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tuberculose / Tuberculose Resistente a Múltiplos Medicamentos / Levofloxacino / Antituberculosos Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tuberculose / Tuberculose Resistente a Múltiplos Medicamentos / Levofloxacino / Antituberculosos Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article